AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 36670495
Drug: Placebo during
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo during oxaliplatin-based chemotherapy
Trial: 36673992
Drug: Nicotine replacement
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine replacement therapy (NRT) use during the initial intervention
Trial: 36674120
Drug: Myofascial release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myofascial release with Findings-Oriented Orthopedic Manual Therapy (OMT) combined with Foam Roller (FR)
Trial: 36678170
Drug: 100 mg/day
RxNorm normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/day ISF Supplement
Trial: 36678170
Drug: 50 mg/day
RxNorm normalized name: infigratinib phosphate 50 mg/day (25 mg x 2) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/day ISF Diet
Trial: 36678170
Drug: ISF Supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ISF Supplement among women enrolled within 5 years of menopause
Trial: 36678191
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg of EGCG daily alone
Trial: 36678191
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg of EGCG daily with clomiphene citrate 100 mg for 5 days
Trial: 36678191
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg of EGCG daily with Letrozole 5 mg for 5 days
Trial: 36678638
Drug: Rifampicin at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampicin at 35 mg/kg (HR35ZE group)
Trial: 36678638
Drug: Rifampicin at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampicin at 10 mg/kg (historical HR10ZE group)
Trial: 36678659
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy applied once a week for four sessions with orabase cream
Trial: 36678659
Drug: Low-power laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-power laser application with orabase cream
Trial: 36679862
Drug: MVC-COV1901 vaccine
RxNorm normalized name: MVC-COV1901
DrugBank: MVC-COV1901 (DB15854)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MVC-COV1901 vaccine (two doses, 28 days apart)
Trial: 36680581
Drug: Fulvestrant 500
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fulvestrant 500 mg + Palbociclib
Trial: 36680581
Drug: Fulvestrant 500
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fulvestrant 500 mg + Placebo
Trial: 36680620
Drug: Ciprofol-0.3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofol-0.3 mg/kg
Trial: 36680620
Drug: Ciprofol-0.4 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofol-0.4 mg/kg
Trial: 36680620
Drug: Ciprofol-0.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofol-0.5 mg/kg
Trial: 36680620
Drug: Propofol-2.0 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol-2.0 mg/kg
Trial: 36680620
Drug: Propofol-2.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol-2.5 mg/kg
Trial: 36680919
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg DHA
Trial: 36681093
Drug: ABNCoV2 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABNCoV2 vaccine (6 μg, 12 μg, 25 μg, 50 μg, or 70 μg)
Trial: 36681093
Drug: ABNCoV2 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABNCoV2 vaccine (25-70 μg)
Trial: 36681093
Drug: ABNCoV2 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABNCoV2 vaccine
Trial: 36681173
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy with acetylsalicylic acid (ASA) and ticagrelor
Trial: 36681173
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy with ASA and ticagrelor
Trial: 36681446
Drug: Low-dose BMMNC
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose BMMNC
Trial: 36681446
Drug: High-dose BMMNC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose BMMNC
Trial: 36681445
Drug: leriglitazone (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: leriglitazone (150 mg starting dose, adjusted to achieve plasma concentrations of 200 μg·h/mL)
Trial: 36681529
Drug: TAK-003 and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-003 and HAV vaccine on Day 1, TAK-003 on Day 90 (Group 3)
Trial: 36681529
Drug: HAV vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAV vaccine and placebo on Day 1, placebo on Day 90 (Group 1)
Trial: 36681529
Drug: Group 1
RxNorm normalized name: Chlamydophila psittaci biogroup 1 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1 (HAV vaccine)
Trial: 36681529
Drug: Group 3
RxNorm normalized name: Chlamydophila psittaci biogroup 3 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 3 (TAK-003 and HAV vaccine)
Trial: 36681529
Drug: Coadministration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coadministration of HAV vaccine and TAK-003
Trial: 36681798
Drug: Metformin extended
RxNorm normalized name: metFORMIN Extended Release Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin extended release (1000 mg/day)
Trial: 36682096
Drug: ODX 3
RxNorm normalized name: Oxycodone hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ODX 3 mg/kg
Trial: 36682096
Drug: ODX 6
RxNorm normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ODX 6 mg/kg
Trial: 36682096
Drug: ODX 9
RxNorm normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ODX 9 mg/kg
Trial: 36682262
Drug: Azithromycin (once-weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (once-weekly oral, weight-based dosing for 48 weeks)
Trial: 36682492
Drug: Digital storytelling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital storytelling intervention (12-min video and five monthly text messages)
Trial: 36682596
Drug: Interruption of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interruption of β-blocker therapy
Trial: 39645270
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of β-blocker therapy
Trial: 36682675
Drug: Music Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music Therapy (MT) intervention, single session for 20-45 minutes
Trial: 36682681
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine (HCQ) 600 mg twice on day 1, followed by 400 mg daily for 29 days.
Trial: 36683090
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of escitalopram (n=32)
Trial: 36683291
Drug: KW-6356 (specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KW-6356 (specific dosage and duration not available)
Trial: 36683419
Drug: AZD7442 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD7442 (300 mg intramuscularly)
Trial: 36683419
Drug: Placebo (salt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (salt solution)
Trial: 36684710
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of power and strength-based exercises
Trial: 36685528
Drug: Targeted-release formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted-release formulation (TRF) of budesonide
Trial: 36685528
Drug: Systemic corticosteroid
RxNorm normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic corticosteroid treatment
Trial: 36685541
Drug: Serplulimab plus
RxNorm normalized name: Serplulimab
DrugBank: Serplulimab (DB17451)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serplulimab plus chemotherapy (etoposide and carboplatin)
Trial: 36686711
Drug: Evolocumab, dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evolocumab, dosage and duration not available
Trial: 36686792
Drug: Carbon nanoparticle
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbon nanoparticle suspension injection (CNSI)
Trial: 36687215
Drug: E-learning intervention
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: E-learning intervention consisting of three modules administered at baseline, 6 and 12 weeks.
Trial: 36687403
Drug: COVID-19 Rehab
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COVID-19 Rehab Formula (CRF) along with certain pre-defined Chinese medicine for 8 weeks
Trial: 36687442
Drug: Gold weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gold weight implant (GWI)
Trial: 36687454
Drug: Pancreatic enzyme
RxNorm normalized name: Pancreatic enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancreatic enzyme supplements (PES) - pancrelipase co-administered with omeprazole
Trial: 36687807
Drug: Individual video-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual video-based case conceptualization with a web-based program based on Acceptance and Commitment Therapy (ACT), combined with treatment as usual.
Trial: 36687807
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual only.
Trial: 36687887
Drug: MCRR therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MCRR therapy for 20 minutes and pelvic floor exercises for 20 minutes, three times a week for 4 weeks.
Trial: 36687887
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (same application as in Group A without emitting any waves) for 20 minutes, three times a week for 4 weeks.
Trial: 36688371
Drug: MEDI6570 (10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI6570 (10, 30, 90, 250, or 500 mg single ascending doses; 90, 150, or 250 mg multiple ascending doses once monthly for 3 months)
Trial: 36688371
Drug: MEDI6570 (after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI6570 (after 3 doses)
Trial: 36689214
Drug: Biosimilar natalizumab
RxNorm normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Biosimilar natalizumab (biosim-NTZ), 300 mg, intravenous infusion every 4 weeks from week 0 to week 44.
Trial: 36689214
Drug: Reference natalizumab
RxNorm normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Reference natalizumab (ref-NTZ), 300 mg, intravenous infusion every 4 weeks from week 0 to week 44.
Trial: 36689692
Drug: Tarlatamab (AMG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tarlatamab (AMG 757), administered in dose exploration (0.003 to 100 mg; n = 73) and expansion (100 mg; n = 34) cohorts
Trial: 36689726
Drug: Acalabrutinib and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acalabrutinib and high-frequency low-dose (HFLD) subcutaneous rituximab 50 mg administered twice a week for 6 cycles of 28 days
Trial: 36689746
Drug: High-dose exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose exercise therapy (patient-tailored exercise programs, 3 times a week for 12 weeks)
Trial: 36689746
Drug: High-dose exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose exercise therapy
Trial: 36689746
Drug: Low-dose exercise
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose exercise therapy (patient-tailored exercise programs, 3 times a week for 12 weeks)
Trial: 36690072
Drug: Liberal transfusion
RxNorm normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liberal transfusion strategy (Hb <10 g/dL to Hb ≥10 g/dL)
Trial: 36690072
Drug: Restrictive transfusion
RxNorm normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive transfusion strategy (Hb <7 g/dL to Hb ≥7 g/dL)
Trial: 36690181
Drug: Cold soda
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold soda water solution
Trial: 36690181
Drug: Any-temperature glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any-temperature glucose solution containing a tea bag
Trial: 36690181
Drug: Room-temperature water-based
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Room-temperature water-based glucose solution
Trial: 36690404
Drug: Dexmedetomidine (DEX)
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine (DEX) infusion at a rate of 0.4 µg/kg/hour until surgical haemostasis
Trial: 36690406
Drug: Letermovir treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letermovir treatment
Trial: 36690734
Drug: Dexamethasone-sparing regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone-sparing regimen with NEPA (netupitant/palonosetron fixed combination)
Trial: 36690839
Drug: TMPRSS6-targeted therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TMPRSS6-targeted therapy (specific intervention details not provided)
Trial: 36690940
Drug: Video-delivered mental
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Video-delivered mental health course based on cognitive behavioral techniques, no specific dosage or duration mentioned.
Trial: 36691000
Drug: Non-operative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-operative treatment (in patients with previous ASBO)
Trial: 36691039
Drug: Virtual reality-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual reality-based cognitive behavioral therapy (VR-CBT)
Trial: 36691039
Drug: Standard cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard cognitive behavioral therapy (CBT)
Trial: 36691127
Drug: Chess-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chess-based cognitive remediation training (CB-CRT) as a therapy add-on for 6 weeks
Trial: 36691127
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual for AUD in a clinic
Trial: 36691127
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual for TUD outpatient treatment
Trial: 36691137
Drug: Er:YAG laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Er:YAG laser therapy with 'Latent inhibition' as anxiety-management technique
Trial: 36691165
Drug: Intravenous ferric
RxNorm normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ferric derisomaltose administered approximately 3 months prior to TAVI
Trial: 36691165
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered approximately 3 months prior to TAVI
Trial: 36691167
Drug: Standard HR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard HR assessment (stethoscope, gel-electrode ECG, pulse oximetry)
Trial: 36691184
Drug: Pre-chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-chemotherapy
Trial: 36692019
Drug: Delayed fractional
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed fractional (DFx) dosing schedule (0-1-6 month)
Trial: 36692019
Drug: Monthly dosing
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly dosing schedule (0-1-2 month)
Trial: 36692475
Drug: Polypharmacy (defined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polypharmacy (defined as the concurrent use of eight or more medications)
Trial: 36692475
Drug: One or
RxNorm normalized name: Geone Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One or more major potential drug interactions (PDIs)
Trial: 36692939
Drug: Virtual Reality
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual Reality Exposure Therapy (VR-ET)
Trial: 36693403
Drug: Oxygen therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen therapy (HFNO or standard oxygen)
Trial: 36693589
Drug: ACT+MBRP (Acceptance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACT+MBRP (Acceptance and Commitment Therapy + Mindfulness-Based Relapse Prevention)
Trial: 36694613
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVIG) followed by steroids
Trial: 36694613
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVIG) followed by anakinra
Trial: 36694613
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVIG) followed by infliximab
Trial: 36695286
Drug: Control (pharmacological
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (pharmacological therapy only)
Trial: 36695396
Drug: Intermediate-dose LMWH
RxNorm normalized name: Prevotella intermedia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermediate-dose LMWH
Trial: 36695396
Drug: Low-dose LMWH
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose LMWH
Trial: 36695625
Drug: ATG monotherapy
RxNorm normalized name: equine ATG
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATG monotherapy (6 or 3 mg/kg body weight) without concomitant immunosuppression
Trial: 36695682
Drug: High-dose cholecalciferol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cholecalciferol (100,000 IU every 2 weeks for 2 months, then monthly for 22 months)
Trial: 36695682
Drug: Low-dose cholecalciferol
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cholecalciferol (12,000 IU every 2 weeks for 2 months, then monthly for 22 months)
Trial: 36696827
Drug: Shorter antimicrobial
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shorter antimicrobial treatment (≤10 days)
Trial: 36696827
Drug: Longer antimicrobial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Longer antimicrobial treatment (>10 days)
Trial: 36696827
Drug: Overall median
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall median duration of antibiotic therapy
Trial: 36696843
Drug: Self-report of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-report of drug use
Trial: 36696843
Drug: Self-report of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-report of drug use among those with positive opioid UDS
Trial: 36697048
Drug: Behavioural economics-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioural economics-based incentives and text messages to support medication adherence
Trial: 36697134
Drug: Somatostatin receptor
RxNorm normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin receptor 2 (SST2) PET/MR imaging
Trial: 36697207
Drug: JNJ-56136379 75
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-56136379 75 mg + nucleos(t)ide analogue (NA)
Trial: 36697207
Drug: JNJ-56136379 250
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-56136379 250 mg + nucleos(t)ide analogue (NA)
Trial: 36697215
Drug: Multidisciplinary rehabilitation
RxNorm normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidisciplinary rehabilitation (MR) consisting of a diagnostic multidisciplinary consultation and eight sessions of physical and occupational therapy.
Trial: 36697694
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of maternal periodontal disease during pregnancy
Trial: 36697694
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (treatment after pregnancy)
Trial: 36698135
Drug: High neutralizing
RxNorm normalized name: DentiCare Neutral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High neutralizing antibody (NAb) titers at days 37, 97, and 187 after symptom onset